Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Karyopharm

Biogen Idec building

Biogen’s Qalsody granted FDA accelerated approval for rare form of ALS

Mutations in the SOD1 gene are responsible for approximately 2% of all cases

Biogen Idec building

Biogen and Eisai’s Alzheimer’s drug associated with positive long-term health outcomes

A simulation model estimated lecanemab to potentially slow the rate of disease progression

Biogen Idec building

Biogen and Eisai’s Alzheimer’s drug to be covered by US Veterans Health Administration

US veterans in the early stages of the disease who meet VHA criteria will be eligible for coverage

- PMLiVE

FDA grants priority review for traditional approval of Biogen and Eisai’s Alzheimer’s drug

Leqembi was granted accelerated approval in the US earlier this year

Biogen Idec building

Safety-related change to label for Biogen’s Alzheimer’s drug Aduhelm approved by FDA

Larger areas of bleeding on the brain have been reported in some patients taking the drug

Biogen Idec building

Biogen and Eisai’s Alzheimer’s drug receives FDA accelerated approval

An application has also been submitted for US approval under the traditional pathway

Biogen Idec building

Biogen and Alcyone Therapeutics partner in deal worth over $50m

The companies hope to improve treatments for spinal muscular atrophy and amyotrophic lateral sclerosis

Biogen Idec building

Biogen and Genentech sign royalty agreement for blood cancer drug glofitamab

Genentech will have sole decision-making rights on glofitamab's commercialisation in the US

- PMLiVE

WHO publishes brief calling for integrated approach to epilepsy treatment

Epilepsy affects over 50 million people globally and accounts for 125,000 death per year

Biogen Idec building

Biogen and Eisai’s Alzheimer’s drug shown to slow memory decline in confirmatory study

The findings have been described as a ‘major step forward’ for dementia research

- PMLiVE

Alzheimer’s Research UK welcomes government’s recommitment to dementia mission

One million people are predicted to be living with dementia by 2025, increasing to 1.6 million by 2040

- PMLiVE

NHS to roll out brain laser therapy for epilepsy patients

There are around 600,000 people living with epilepsy across the UK

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links